Jagsonpal Pharmaceuticals Ltd. reported a healthy start to FY27, posting an 8.8% year-on-year increase in revenue to Rs. 82.2 crore for the quarter ended June 30, 2026, while profit after tax (PAT) rose 22.2% to Rs. 13.2 crore, driven by improved operating efficiencies and continued strength across its key brands. 

The company reported operating EBITDA of Rs. 19.1 crore, up 21.4% year-on-year, with the operating EBITDA margin expanding 241 basis points to 23.2%, reflecting higher medical representative productivity and operating leverage.

The company also maintained a healthy cash balance of Rs. 170 crore, despite completing a Rs. 40 crore share buyback and funding the acquisition of Aequitas Healthcare through internal accruals. 

Manish Gupta, Managing Director and CEO, said the company continued to outperform the Indian pharmaceutical market, with Pharmarack reporting 18.9% growth for Jagsonpal compared with 11.6% for the Indian Pharmaceutical Market (IPM). The performance helped the company improve its ranking by four places to No. 88 in the Indian pharmaceutical market.

Gupta added that Jagsonpal recently completed the acquisition of an 85% controlling stake in Aequitas Healthcare, marking its entry into the hospital supplies segment. He noted that despite the acquisition and buyback, the company ended the quarter with a strong cash position, providing the flexibility to pursue future value-accretive inorganic opportunities. 

The acquisition of Aequitas Healthcare is expected to significantly strengthen Jagsonpal's specialty portfolio and provide immediate access to more than 1,000 hospitals across India.

Starting with Aequitas' FY26 revenue base of Rs. 53.3 crore, the company expects higher revenue contribution from the second half of FY27 and is targeting EBITDA of over Rs. 10 crore by the second year following integration through cross-selling opportunities, operational synergies and improved profitability. 

The company said its strong balance sheet, disciplined capital allocation and expanding specialty portfolio position it well to sustain profitable growth while accelerating its presence in the hospital-focused pharmaceutical segment.